Year: 2022

Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

Finalized pivotal Phase 3 trial design following formal meetings with FDAReceived FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic...

error: Content is protected !!